CMS and the Medicare private drug plans are using Medicare enrollment to teach seniors -- and their adult advisors -- about the cost savings from therapeutic interchange. Training patients to look for cost savings and to discuss costs with doctors is clearly a secondary objective of the Medicare enrollment process. The Medicare plan finder website and private plan sites carry frequent messages to alert beneficiaries cost savings. Pfizer responds with consumer-based pricing for Lipitor.
Cole Werble
School started Nov. 15 for an accelerated course in pharmaceutical pricing and product switching.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.
A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
